These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 1657828)

  • 41. Use of anti-D in general practice.
    Russell DR
    Br J Gen Pract; 1990 Feb; 40(331):81. PubMed ID: 2156544
    [No Abstract]   [Full Text] [Related]  

  • 42. An audit of anti-D sensitisation in Yorkshire.
    McSweeney E; Kirkham J; Vinall P; Flanagan P
    Br J Obstet Gynaecol; 1998 Oct; 105(10):1091-4. PubMed ID: 9800932
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antepartum Rh immune globulin.
    Wible-Kant J; Beer AE
    Clin Perinatol; 1983 Jun; 10(2):343-55. PubMed ID: 6311476
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anti-D immunoglobulin prophylaxis--are we doing enough?
    Drug Ther Bull; 1985 Dec; 23(24):93-5. PubMed ID: 2998720
    [No Abstract]   [Full Text] [Related]  

  • 45. Alloimmunization in pregnancy during the years 1992-2005 in the central west region of Sweden.
    Gottvall T; Filbey D
    Acta Obstet Gynecol Scand; 2008; 87(8):843-8. PubMed ID: 18704776
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Spontaneous or induced abortion and the risk of Rh immunization].
    Keith L; Berger GS
    Contracept Fertil Sex (Paris); 1982 May; 10(5):323-31. PubMed ID: 12338185
    [TBL] [Abstract][Full Text] [Related]  

  • 47. RCM challenges new anti-D guidelines.
    Pract Midwife; 1999 Nov; 2(10):7. PubMed ID: 12024565
    [No Abstract]   [Full Text] [Related]  

  • 48. Incidence of maternal sensitisation to Rh(D) in Christchurch, New Zealand and reasons for prophylaxis failures.
    Badami KG; Parker J; Kenny A; Warrington S
    N Z Med J; 2014 Jan; 127(1388):40-6. PubMed ID: 24481385
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Compliance with routine antenatal rhesus D prophylaxis and the impact on sensitisations: observations over 14 years.
    MacKenzie IZ; Findlay J; Thompson K; Roseman F
    BJOG; 2006 Jul; 113(7):839-43. PubMed ID: 16827770
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Risks of prophylactic anti-D immunoglobulin after second-trimester amniocentesis.
    Tabsh KM; Lebherz TB; Crandall BF
    Am J Obstet Gynecol; 1984 May; 149(2):225-6. PubMed ID: 6326576
    [No Abstract]   [Full Text] [Related]  

  • 51. [Expanded rhesus prophylaxis].
    Maroni ES
    Schweiz Rundsch Med Prax; 1987 Nov; 76(45):1254-9. PubMed ID: 2827286
    [No Abstract]   [Full Text] [Related]  

  • 52. Clinical validation of routine antenatal anti-D prophylaxis questions the modelling predictions adopted by NICE for Rhesus D sensitisation rates: results of a longitudinal study.
    Mackenzie IZ; Roseman F; Findlay J; Thompson K; McPherson K
    Eur J Obstet Gynecol Reprod Biol; 2008 Jul; 139(1):38-42. PubMed ID: 18243487
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Use of anti-D (Rh) IgG or intramuscular polyvalent human immunoglobulin in the treatment of chronic autoimmune thrombocytopenic purpura].
    Vizcaíno G; Diez-Ewald M; Arteaga-Vizcaíno M; Torres E
    Invest Clin; 1992; 33(4):165-74. PubMed ID: 1338940
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Society of Family Planning committee consensus on Rh testing in early pregnancy.
    Horvath S; Goyal V; Traxler S; Prager S
    Contraception; 2022 Oct; 114():1-5. PubMed ID: 35872236
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Immuno-elimination and clearance of Rh-positive erythrocytes in Rh-negative volunteers following administration of anti-D-immunoglobulin].
    Maas DH; Weitzel HK; Stolp W; Hünermann B; Schneider J
    Geburtshilfe Frauenheilkd; 1983 Mar; 43(3):164-70. PubMed ID: 6305763
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The economics of routine antenatal anti-D prophylaxis for pregnant women who are rhesus negative.
    Chilcott J; Tappenden P; Lloyd Jones M; Wight J; Forman K; Wray J; Beverley C
    BJOG; 2004 Sep; 111(9):903-7. PubMed ID: 15327602
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Immunohematological surveillance of the pregnant woman: new prevention policy].
    Mannessier L
    Transfus Clin Biol; 2009 May; 16(2):195-200. PubMed ID: 19419894
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reported management of early-pregnancy bleeding and miscarriage by general practitioners in Victoria.
    Mclaren B; Shelley JM
    Med J Aust; 2002 Jan; 176(2):63-6. PubMed ID: 11936286
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Anti-D prophylaxis in fetal-maternal erythrocyte incompatibility in Tunisia].
    Ksibi I; Achour R; Bel Haj Ammar W; Cheour M; Ben Amara M; Neji K; Kacem S
    Arch Pediatr; 2017 Oct; 24(10):942-949. PubMed ID: 28893486
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prevention of Rhesus-D Alloimmunization in the First Trimester of Pregnancy: Economic Analysis of Three Management Strategies.
    Dochez V; Chabernaud C; Schirr-Bonnans S; Riche VP; Thubert T; Winer N; Vigoureux S
    Transfus Med Rev; 2024 Jan; 38(1):150778. PubMed ID: 37925226
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.